Key Highlights:
- Lantern Pharma announced the launch of an AI Center of Excellence and Advanced Agentic Labs in Bengaluru, India, aimed at scaling its AI-driven drug discovery platform and supporting collaborations with global pharmaceutical partners.
- The center will expand capabilities of the company’s proprietary RADR AI Platform, which analyzes hundreds of billions of oncology data points and integrates machine learning algorithms to support biomarker discovery, molecular optimization, and clinical trial design.
- Initially focused on accelerating oncology programs, the platform will later expand into additional therapeutic areas such as lupus, rheumatoid arthritis, and Alzheimer’s disease, leveraging Bengaluru’s growing ecosystem of AI engineers, data scientists, and computational biologists.
Implications:
Lantern’s Bengaluru expansion accelerates U.S. biotech offshoring of AI-drug discovery to India, intensifying talent competition with Dr. Reddy’s and Biocon while cutting oncology R&D costs by 40-50% via local engineers.
This could shortcut clinical timelines for Lantern’s partners (e.g., PDF for LP-284), pressuring traditional CROs and boosting India’s $2B+ AI-pharma services market.
Long-term, it positions Bengaluru as Asia’s AI-oncology hub, drawing PE investments into nephrology/rare disease AI platforms amid global trial delays.
Source: Businesswire
Other Articles
Next
Previous
No Comment! Be the first one.